Niagen Bioscience Rebrands Research Program to Strengthen NAD+ Science Leadership — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience renamed its ChromaDex External Research Program to the Niagen Research Program, reflecting its evolution as a leader in NAD+ science.
The program has supported 300+ research collaborations and 45+ human clinical studies, advancing NAD+ science into clinically relevant tissues and systems.
Independent investigators from institutions like Mayo Clinic, NIH, Harvard, MIT, and Cambridge University have used the program for NAD+ research.
The company launched the Niagen Bioscience Trainee Grant Program, awarding $10,000 grants to graduate students and postdoctoral trainees.
Priority research areas include dermatologic science, cognitive function, cellular energy metabolism, cardiovascular health, and pharmaceutical-grade injectable Niagen.

The big picture

Niagen Bioscience's rebranding of its research program underscores its commitment to advancing NAD+ science, a key area in healthy aging. The company's focus on rigorous scientific collaboration and clinical rigor positions it as a leader in the biotech industry. With over 300 research collaborations and 45 clinical studies, Niagen Bioscience is well-positioned to capitalize on the growing interest in NAD+ and its applications in various health areas.

What we're watching

Research Expansion: How the Niagen Research Program will scale its 175+ ongoing studies and attract more independent investigators.
Regulatory Compliance: Whether Niagen Bioscience can maintain its position on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B list.
Market Penetration: The pace at which Niagen can grow its consumer supplement, Tru Niagen, and pharmaceutical-grade Niagen Plus products.